Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España

Actualizado enero 2024

Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Para iniciar la búsqueda, teclee el texto en la barra a continuación.

UNK4985604DAY101-102A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations.
Thyroid Cancer, Papillary
Phase I / IIThis is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.RECLUTANDOTovorafenib
H. Clinic Barcelona
H. U. Vall d'Hebron
H. U. Ramón y Cajal
Day One Biopharmaceuticals, Inc.
UNK4731467FW-2020-1A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid TumorPhase I / IICohort: Papillary Thyroid CancerRECLUTANDOCM-24
Nab paclitaxel Gemcitabine
H. Vall d' Hebron(BCN)
H. 12 Octubre(Madrid)
H. Quiron Valencia
H. Clinic (BCN)
Next_Quirón (Madrid & BCN)
H.G.Marañón (Madrid)
Start_F J Diaz (Madrid)
Famewave Ltd
Bristol-Myers Squibb
2016-003616-133093116TPX-0005-01A Study of Repotrectinib (TPX-0005)
in Patients With Advance Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Phase IIPhase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts.
RECLUTANDORepotrectinib (TPX-0005)C.U.N.
H.U. Dexeus (Barcelona)
H.U. Vall d´Hebron (Barcelona)
M.D. Anderson (Madrid)
Start_F.J.Díaz (Madrid)
Start_Sanchinarro (Madrid)
H.U. 12 de Octubre (Madrid)
IVO Valencia
Turning Point Therapeutics, Inc.
CTIS: 2022-500397-34-00
26280673475-158A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Phase IIThyroid Carcinoma
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
RECLUTANDOPembrolizumabH.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
H. V. de la Victoria (Málaga)
Merck Sharp & Dohme Corp
2020-001847-164589845BO41932Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialPhase IITreatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.RECLUTANDOPralsetinib

H. Vall d´Hebron (Barcelona)
H. 12 de Octubre (Madrid)
H.La Paz (Madrid)
H. la Fe (Valencia)
Hoffmann-La Roche
UNK5660954GETNE-T2216Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.Phase IICABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine refractoryRECLUTANDOCabozantinibH. U. Central de Asturias
H. U. Rey Juan Carlos (Madrid)
C. H. U. A Coruña
H. U. Vall d'Hebron
H. Clínic de Barcelona
H. U. Ramón y Cajal
H. C. San Carlos (Madrid)
H. U. 12 de Octubre
H. Morales Meseguer (Murcia)
C.H de Salamanca
Grupo Espanol de Tumores Neuroendocrinos
UNK3906331J2G-OX-Y001Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationExpanded AccessMedullary Thyroid Cancer
Papillary Thyroid Cancer
Other Solid Tumors With Evidence of Activating RET Alteration
DISPONIBLESelpercatinibH.U. Vall d´Hebron (Barcelona)
Start_Sanchinarro (Madrid)
Loxo Oncology, Inc.
N.A3765333REGETNE-TiroidesDescriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and AnaplasticDescriptive ObservationalNARECLUTANDONAH.U. Vall d´Hebron (Barcelona)Grupo Espanol de Tumores Neuroendocrinos

Puede seleccionar el número de filas a representar entre: 4, 8 o 10